bearish
Align Technology (ALGN US): Q3 Result Not Aligned with Consensus; Outlook Remains Cloudy
183 Views27 Oct 2022 19:28
SUMMARY
- On a constant-currency basis, Q3 revenue of Align Technology (ALGN US) was reduced by 3% sequentially and 6% year-over-year, one of the largest quarterly foreign exchange impacts.
- Weak consumer sentiment is taking a toll on Invisalign shipment, with adult case starts plunging 11% q/q and 16% y/y to 377K. Invisalign ASPs nosedived to nine-quarter low of $1,150.
- Amid increasing competition and macroeconomic headwinds, long-term model of 20–30% revenue growth is hard to achieve. The company is also expected to miss 2022 operating margin target of 20%.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Align Technology - Very Well Positioned when Demand Returns15 Jan 2023
- Align Technology (ALGN US): Q3 Result Not Aligned with Consensus; Outlook Remains Cloudy27 Oct 2022
- Align Technology (ALGN US) Q1 Results: Both Revenue and Earnings Miss, First Time in Last Two Years28 Apr 2022
- Align Technology (ALGN US) Vs. Angelalign Technology (6699 HK): Which One Is Better Investment02 Mar 2022
x